Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy
—Data Presented at AED Xll Meeting Confirms INS001 Appears Safe and Well Tolerated—, —Preparations for Phase II Proof of Principle Trial Underway—,
Data on Cook Medical Products Presented at Digestive Disease Week®
At this week’s Digestive Disease Week (DDW), the world’s largest gathering of physicians and researchers in the gastroenterology field, six abstracts and other clinical data will be presented on Cook Medical products. Cook’s EchoTip® ProCore™ High Definition Ultrasound Biopsy needles are featured in many of these presentations.
-
-
Santarus Announces UCERIS (budesonide) Poster Presentations at Digestive Disease Week Meeting
Santarus, Inc. (NASDAQ: SNTS) today announced that additional data from two pivotal clinical studies with UCERIS® (budesonide) extended release tablets will be featured in two poster presentations at the Digestive Disease Week® (DDW®) Meeting being held in Orlando, Fla. from May 18 – 21, 2013.
-
Stem Cell Action Coalition Applauds Cloned Stem Cell Breakthrough
The Stem Cell Action Coalition, a network of 75 nonprofit disease advocacy groups, scientific societies and academic centers, applauds the researchers at the Oregon Health and Science University for their groundbreaking accomplishment of producing stem cells utilizing the process of somatic cell nuclear transfer (SCNT).
-
TherapeuticsMD Elects Jules A. Musing to Board of Directors
TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women’s healthcare company focused on developing and commercializing products targeted exclusively for women, today announced the election of Jules A. Musing, a former senior executive at Johnson & Johnson, to its Board of Directors, effective immediately.
-
Dyadic International Reports First Quarter 2013 Financial Results
-- Signs Landmark Research & License Agreement with BASF (subsequent event) --, -- Enzyme Product Sales Up 20% Y/Y --, -- Cash Balance Up 3% from December 31, 2012 --, -- Expects Revenue Growth and Profitability for Full Year 2013 --, -- Strengthens Manag
-
Entia hires director of marketing for medical foods and consumer products
Expanded GROH® line to be launched at Intercoiffure America/Canada May 19th & 20th
-
BASF And Dyadic International Enter Into A Research And License Agreement
Dyadic's C1 Technology Platform Enables BASF to Develop Enzymes for Multiple Market Segments
-
Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2013
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) announced today they will present linaclotide-related data during Digestive Disease Week® 2013 in Orlando, Fla., May 18 through May 21, 2013. Among the data highlighted will be two oral presentations: one providing insight into the GC-C/cGMP pathway in patients with IBS-C and another describing the effects of linaclotide on inhibiting visceral pain, both based on nonclinical studies.
-
Sucampo Pharmaceuticals to Host Update on AMITIZA® OIC Indication May 20th
Sucampo Pharmaceuticals, Inc. (“Sucampo”) (NASDAQ: SCMP), a global pharmaceutical company, today announced that it will host a meeting to discuss the recent opioid-induced constipation (OIC) indication approval for its flagship product, AMITIZA, on May 20, 2013, from 9:00 to 10:30AM ET in Orlando, FL. Members of Sucampo’s management team and two key outside experts will provide a market update, overview of the scientific data, and clinical perspectives relevant to OIC.
-
RBCC Partner n3D Signs U.S. Distribution Agreement
Rainbow Coral Corp. (OTCBB: RBCC) received word this week that the revolutionary technology developed by its partner, Nano3D Biosciences (n3D), is set to begin penetrating the U.S. marketplace.
-
CleanPath Resources Corp Announces Preliminary Research Report on New Stem Cell Enhancement Product NutraLoad™
/PRNewswire/ -- CleanPath Resources Corp (OTC Pink: CLNP) (www.re-load.biz) CleanPath Resources' newest research and development partner, BioSwan, Inc., just announced new research initiatives for its stem cell enhancement product NutraLoad™. The next phase of research will take place in Europe and Asia and will be focused on NutraLoad™'s efficacy on targeted health issues.
-
TherapeuticsMD Reports First Quarter 2013 Financial Results
TherapeuticsMD, Inc. (NYSE MKT:TXMD), a women’s healthcare company focused on developing and commercializing products targeted exclusively for women, today announced financial results for the three months ended March 31, 2013.
-
Dyadic International To Announce First Quarter 2013 Financial Results And Host Conference Call On Wednesday, May 15, 2013
/PRNewswire/ -- Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company, today announced that it will report its financial results for the first quarter ended March 31, 2013 after market close on Wednesday, May 15, 2013 and will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results.
-
VGTI Florida Scientist Selected for a Peer-Review Panel for the National Institutes of Health
Keith Knutson, Ph.D., Program Director, Oncology, of the Vaccine & Gene Therapy Institute of Florida (VGTI Florida™) was selected as a new committee member to the National Institutes of Health (NIH) Tumor Microenvironment (TME) Study Section with the Center for Scientific Review (CSR).
-
Xcovery Vision Presents VEGFR/PDGFR Oral Inhibitor X-82 Preliminary Data for Wet AMD at ARVO
Pilot Clinical Data Shows Dose Well Tolerated, Potentially EfficaciousOral, Once Daily VEGFR/PDGFR Pilot Clinical Study Enrolling
-
Danai Brooks Joins Dyadic International As Chief Operating Officer
/PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the industrial enzyme, bioenergy, and biopharmaceutical industries, announced today that Danai Brooks will join the Company as Executive Vice President and Chief Operating Officer in June. Brooks joins Dyadic from J.P. Morgan where he served as a Vice President in the firm's Investment Bank.
-
Danai Brooks Joins Dyadic International as Chief Operating Officer
/PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the industrial enzyme, bioenergy, and biopharmaceutical industries, announced today that Danai Brooks will join the Company as Executive Vice President and Chief Operating Officer in June. Brooks joins Dyadic from J.P. Morgan where he served as a Vice President in the firm's Investment Bank.
-
Increased Dosage of Needle-Free Erectile Dysfunction Medication TriMix-gel Now Available through KRS Global Biotechnology
/PRNewswire/ -- TriMix Laboratories, LLC and KRS Global Biotechnology, INC today announced the availability of TriMix-gel® in a 2000 microgram dose. The joint developmental effort is the result of physicians and patients asking if it was possible for TriMix-gel to come in an increased dosage. After development and testing, the new dosage is available immediately from KRS Global Biotechnology on the prescription of a licensed physician.
-
Islet Sciences Highlights Abstract at Arteriosclerosis, Thrombosis & Vascular Biology ATVB 2013
Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today the acceptance and presentation of an abstract at the recent Arteriosclerosis, Thrombosis & Vascular Biology (ATVB) 2013. The abstract is titled: Signal Transducer and Activation of Transcription (STAT) 4 deficiency reduces adipose tissue inflammation and atherosclerosis.
Marketplace
RSS|
My Yahoo|
Newsletters|
Mobile|
Alerts|
Twitter
Terms of Service| Privacy Policy| About our ads| Copyright| About The Miami Herald| About the McClatchy Company| Corrections| Contact Us| Advertise| Work for Us
Partners: El Nuevo Herald| Newspaper in Education| WLRN | Miami Herald News| CBS4 WFOR-TV| More
Copyright 2013 Miami Herald Media Co. All rights reserved